1952 — Everest Medicines Share News
0.000.00%
Last trade - 00:00- HK$11.47bn
- HK$11.42bn
- CNY1.71bn
Brief: Everest Medicines Entered Strategic Collaboration With Meditrust Health
Brief: Everest Medicines Makes Strategic Collaboration With Medbanks Health Technology
Brief: Everest Medicines Entered Strategic Commercial Partnership With Tencent Holdings Ltd
Brief: Everest Medicines Announces That Spero Therapeutics Entered Into Licensing Agreement With Pfizer Inc. For Spr206 In Ex-U.S. And Ex-Asia Territories
Brief: Everest Medicines Says Sacituzumab Govitecan-Hziy Granted Priority Review
Brief: Everest Medicines Says South Korea Granted Orphan Drug Designation For Sacituzumab Govitecan-Hziy
Brief: Everest Medicines Says US FDA Granted Accelerated Approval Of Trodelvy To Gilead Sciences
Brief: Everest Medicines Says U.S. FDA Granted Full Approval Of Trodelvy To Gilead Sciences
Brief: Everest Medicines Says NMPA Approved Clinical Trial Application
Brief: Everest Medicines Posts FY Loss Attributable RMB5.66 Bln Versus Loss Of RMB214.5 Mln
Brief: Everest Medicines Says China's NMPA Accepts New Drug Application For Xerava
Brief: Everest Medicines Initiates Submission Of New Drug Application In Singapore For Sacituzumab Govitecan-Hziy
Brief: Everest Medicines Says NMPA Approved A Clinical Trial Application For Sacituzumab Govitecan-Hziy
Brief: Everest Medicines Says Center For Drug Evaluation Of NMPA Recommended Breakthrough Therapy Designation For Nefecon
Brief: Everest Medicines Says NMPA Approved Clinical Trial Application For Trodelvy
Brief: Everest Medicines Announces Completion Of Phase 3 Bridging Clinical Trial Of Xeravatm (Eravacycline)
Brief: HBM Healthcare Investments Says Everest Medicines Completed Its Announced IPO On Hong Kong Stock Exchange
Chinese biotech firm Everest Medicines shines in Hong Kong debut